Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CroatiaBack to Croatia

Clinical trials in Osijek – page 4

85 clinical trials in Osijek, Croatia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Osijek at a glance
85
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

85 trials in Osijek

Open in trial search

Tardive dyskinesia

Not yet recruiting

Study on the Effects of (+)-α-Dihydrotetrabenazine for Treating Tardive Dyskinesia in Patients with Schizophrenia, Mood, or Gastrointestinal Disorders

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:(2R,3R,11Br)-1,3,4,6,7,11B-Hexahydro-9,10-Dimethoxy-3-(2-Methylpropyl)-2H-Benzo[A]Quinolizin-2-Ol
  • Sponsor:Adeptio Pharmaceuticals Limited

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of Lutikizumab and Adalimumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:CroatiaCroatia
  • Participants:0–17 years
  • Sponsor:Amgen Inc.

Psoriatic arthropathy

Not recruiting

Study on the Effects and Safety of Guselkumab for Patients with Active Psoriatic Arthritis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Acute haemorrhagic ulcerative colitis

Not recruiting

Study Comparing AVT16 and Vedolizumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Alvotech Swiss AG

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Roflumilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Psoriatic arthropathy

Not recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Rosnilimab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Rosnilimab
  • Sponsor:Anaptysbio Inc.

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Osijek

What the registry says about research in the country

01 Autoimmune Disorders

Clinical research focusing on innovative treatments for psoriatic arthritis, systemic sclerosis, and Sjögren's Syndrome. Studies evaluate new therapeutic approaches targeting specific immune pathways.

  • Psoriatic Arthritis Treatment
  • Systemic Sclerosis Management
  • Sjögren's Syndrome Therapy

Investigations include both biologic and non-biologic treatment options for patients with varying disease severity.

02 Gastrointestinal Disorders

Comprehensive studies examining treatments for Crohn's Disease and Ulcerative Colitis. Research focuses on novel therapeutic compounds and combination treatments.

  • Inflammatory Bowel Disease Management
  • Novel Treatment Combinations
  • Pediatric Gastrointestinal Conditions

Trials aim to improve clinical outcomes and quality of life for patients with moderate to severe disease.

03 Neurological Conditions

Advanced research into Multiple Sclerosis and tardive dyskinesia treatments. Studies evaluate new therapeutic approaches and compare treatment efficacy.

  • MS Treatment Innovations
  • Movement Disorders
  • Neurological Disease Management

Focus on developing treatments that can slow disease progression and improve symptoms.

Back to CroatiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.